LONDON (18 April 2023) – MMS Holdings, a data-focused contract research organization (CRO), has been named a Great Place to Work-Certified™ organization in the UK. This comes as the number of MMS colleagues based in the UK has doubled in just one year. “We are...
CANTON, Mich. (March 21, 2023) – MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors. Both industry leaders in innovative clinical trial delivery solutions,...
CANTON, Mich. (February 21, 2023) - MMS, a data-focused contract research organization (CRO) - announced its partnership with the Institute for Advanced Clinical Trials (I-ACT) to accelerate the development of life-saving therapeutics including vaccines, medicines,...
CANTON, Mich. (2/7/2023) – MMS Holdings (MMS) – an award-winning, data-focused contract research organization (CRO) – announces the expansion of its leadership team with the appointment of Chris Schoonmaker as Chief Operating Officer and Ashu Tandon as Chief...
BANGALORE, India (1/12/2023) – MMS Holdings, a data-focused contract research organization (CRO), has been named a Great Place to Work by the Great Place to Work Institute of India. This award is based on anonymous feedback from a survey sent out to employees and...
CANTON, Mich. (11/21/2022) – MMS Holdings, a data-focused contract research organization (CRO), has been named a 2022 award winner of the Michigan Top Workplaces by the Detroit Free Press Top Workplaces. This is the second year that MMS has been recognized with this...
CANTON, Mich. (8/16/2022) – The TOGETHER Trial, which uses an Electronic Data Capture (EDC) system designed, built, and maintained by MMS Holdings, a data-focused contract research organization (CRO), won the Society for Clinical Trial’s annual Trial of the Year Award...
The partnership will help MMS expand its award-winning services to pharma and biotech companies and extend MMS’ leadership in data-focused clinical research services. CANTON, Michigan – June 28, 2022 – MMS Holdings Inc. (“MMS” or the “Company”), a leading data-focused...
On PTSD Awareness Day, MAPS PBC announces plans to develop the New Drug Application for MDMA-assisted therapy in collaboration with MMS Holdings The second Phase 3 trial of the Breakthrough-Designated Therapy for PTSD will be completed in late 2022, with a targeted...